Level D· Scientific groundwork from lab and animal studiesAnimal StudyPubMed

Immunomodulatory and neuroprotective effects of miR-146a-enriched MSC-derived extracellular vesicles in experimental autoimmune encephalomyelitis.

Shahryari F., Jafarinia M., Jafarinia M., Azimzadeh M.

Animal Study on Neuroinflammation, Chronic Inflammation, Immune Modulation, Autoimmune Research, published in Int Immunopharmacol (2025) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
Int Immunopharmacol (2025)
Country
Netherlands
Reported sample size
—
Source database
PubMed
PMID
40991997
DOI
10.1016/j.intimp.2025.115584

Abstract (original English)

Mesenchymal stem cell-derived extracellular vesicles (MSC-EVs) have emerged as promising cell-free therapeutics due to their immunomodulatory and reparative properties, especially through microRNAs (miRNAs). This study investigates the therapeutic potential of EVs enriched with miR-146a-EVs, a key regulator of inflammatory signaling, in experimental autoimmune encephalomyelitis (EAE), a murine model of MS. Human adipose-derived MSCs (hADSCs) were transfected with miR-146a mimics or miR-control, and their EVs were isolated. After EAE induction in C57BL/6 mice, they were treated intravenously with miR-146a-enriched EVs, control EVs, or PBS. Clinical scores were monitored for 30 days. Cytokine levels (tumor necrosis factor (TNF)-α, interferon-gamma (IFN-γ), interleukin (IL)-17, IL-4, IL-10, transforming growth factor beta (TGF-β)) were measured in splenocytes and spinal cord tissue using enzyme-linked immunosorbent assay (ELISA) and quantitative polymerase chain reaction (qPCR), respectively. Histopathology (Hematoxylin and Eosin (H&E), Luxol Fast Blue (LFB)) and immunohistochemistry (Myelin Basic Protein (MBP)) assessed inflammation and demyelination. miR-146a-enriched EVs significantly attenuated EAE severity, reducing pro-inflammatory cytokines (TNF-α, IFN-γ, IL-17) and elevating anti-inflammatory cytokines (IL-10, TGF-β) in both splenocyte cultures and spinal cord tissue. The

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
AnimalsMicroRNAsEncephalomyelitis, Autoimmune, ExperimentalExtracellular VesiclesMesenchymal Stem CellsMice, Inbred C57BLHumansMiceCytokinesFemale

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research